Plasma concentrations and total amounts of pregnancy associated plasma protein A were determined in 272 patients at 34 weeks' gestation by immunoelectrophoretic assay. The mean plasma concentration and mean total amount of this protein were closely related (r=0 9643) and were significantly raised in patients who subsequently developed pre-eclampsia (28 patients), went into premature labour (12), or suffered from antepartum haemorrhage (10). Mean values in all patients delivering growth-retarded babies were also raised, but when the results for such patients who also had other complications were excluded there were no differences between the sets of means.
Introduction
In 1973 Lin et all isolated a new protein from the plasma of pregnant women. This protein, which they named pregnancy associated plasma protein A (PAPP-A) was, like the protein hormones human placental lactogen and human chorionic gonadotropin, peculiar to pregnancy and produced in the placenta.2 The concentration increased with the growth of the placenta as pregnancy advanced.3 The Miami group have protein5 and have investigated the possibility of using this assay to screen large numbers of patients by a single measurement in late pregnancy.
Patients and methods
Patients in Aberdeen Maternity Hospital receiving antenatal care under a combined scheme with their general practitioners are reviewed in hospital when they are 34 weeks pregnant. We took venous blood samples at random from 272 such patients. The results of the assays did not influence management of these patients. After delivery data about the pregnancy were taken from the case records.
Venous blood samples (10 ml) were taken and put into heparinised containers. The plasma was removed the same day and stored at -20'C until the analysis was performed. PAPP-A concentrations were measured by the Laurell "rocket" method of immunoelectrophoresis,5 with a monospecific antiserum to PAPP-A raised by injecting the purified protein into rabbits.6 The standard was a pool of latepregnancy plasma calibrated against the pure protein. We have aliquots of a similar standard available for researchers wishing to calibrate their own standard.
Results
The 272 patients studied were divided into two groups: 176 who had normal pregnancies and 96 who developed some clinical obstetric abnormality. Some of the 96 already presented evidence of obstetric disease at the time of the 34-week examination or earlier. We excluded from the analysis those who presented with pre-eclamptic toxaemia or a history of antepartum haemorrhage before 34 weeks, six patients with essential hypertension, five who delivered sets of twins, and three diabetics. We included in the analysis 28 patients who developed pre-eclampsia (blood pressure above 140/90 mm Hg) and 10 patients who suffered an antepartum haemorrhage, however slight, after 34 weeks. Only two of the patients with pre-eclampsia were considered to be suffering from severe pre-eclampsia-that is, had albuminuria as well as hypertension. We included a further 12 patients who went into spontaneous labour before 37 weeks (preterm labour) and 38 who produced growth-retarded babies according to the criteria laid down for the Aberdeen population by Thomson et al.7 There was some overlap between the growth-retarded category and other categories: three of these patients also had antepartu-m haemorrhage, two developed pre-eclampsia, and one went into labour prematurely. Three of the growth-retarded babies were malformed. Table I shows the mean and standard deviation of PAPP-A values in the various categories. On inspection of the values in the normal group we found that the distribution of data was skewed, with values tending to cluster below the mean, which was increased by a few exceptionally high results. A similar finding has been recorded with other placental proteins such as human placental lactogen.8 Log transformations were therefore performed-in determining the statistics of this material. An attempt was also made to get a more reliable result for the placental production of PAPP-A by allowing for the different maternal plasma volumes in which the protein was distributed. This was achieved by multiplying the plasma PAPP-A concentration by the woman's body weight, giving a result representing the total amount of PAPP-A. Values for the total PAPP-A and the plasma concentration were closely related (r=0 9643), and information derived from total PAPP-A values was similar to that derived from PAPP-A concentrations. *Total PAPP-A = plasma concentration (,ug/ml) x body weight (kg).
Significance of differences from normal: t2p < 0 05, +2p < 0-001, §2p < 0 03.
is a major cause of perinatal fetal loss, and it is of particular interest that the plasma PAPP-A concentration has some predictive value for the development of this disease. The fact that the test does not require advanced technology, expensive instruments, or radioactive materials is an attractive feature. The protein is stable at room temperatures, and hospital laboratory centres could provide a rural service by post. PAPP-A is a placental protein, and its concentration in maternal plasma probably reflects placental activity. Not surprisingly, therefore, the assays are of no value in diagnosing fetal growth retardation, a disease that often has a primary fetal element. Indeed, the coexistence of growth retardation and pre-eclampsia may impair the value of the test in predicting pre-eclampsia.
The potential of PAPP-A assays cannot be realised until more information on the physiological function of the protein is available. Klopper et a19 have suggested that it is a locally active compound performing a function, presumably immunosuppressive, at the trophoblast-decidual interface. It probably does not enter the maternal circulation by active secretion from the chorionic villi into the retroplacental blood but by dissolution of migrating or embolic trophoblast within the maternal tissues.9 Perhaps the association of raised PAPP-A values with preterm labour is not causal but a consequence of increased uterine activity preceding the onset of labour. PAPP-A values were raised above normal in patients who subsequently developed pre-eclampsia, went into preterm labour, or suffered an antepartum haemorrhage. Values in the abnormal group as a whole were also raised, but this group was so heterogeneous that this finding largely reflected the numerical distribution of the subgroups composing it. The patients with growth-retarded babies were also a mixed group, and when patients with complications such as pre-eclampsia or antepartum haemorrhage were excluded the mean PAPP-A values for patients in this group were not raised. Table II shows the percentage of patients in each category who had values above the 80th, 85th, 90th, and 95th percentiles of the log transforms. Sixty per cent of patients who would later develop pre-eclampsia already had values above the 80th percentile by 34 weeks, and 25% had values greater than the 95th percentile. Half the women who went into preterm labour had values greater than the 80th percentile, as did 300o of patients who subsequently had some antepartum bleeding. Thirty-four per cent of all patients who delivered a growth-retarded baby had values above the 80th percentile, but when patients who also had pre-eclampsia and antepartum haemorrhage were excluded from this group the figure fell to 26%, which was barely above the normal incidence.
Discussion
Our findings suggest that PAPP-A assays may be a useful screening technique for detecting a group at risk requiring special surveillance in antenatal care. Pre-eclamptic toxaemia often been invoked in pre-eclampsia, and there is increasing evidence that PAPP-A participates in the immunological interaction between trophoblast and maternal tissues.1" If PAPP-A is indeed a locally active and non-toxic biological immunosuppressive agent it raises many possibilities in subjects such as transplant surgery. The function of this protein should be thoroughly investigated. " Bischof P. Observations on the isolation of pregnancy-associated plasma protein A. In: Klopper A, Chard T, eds. Placental proteins. Heidelberg: Springer-Verlag, 1979:105-18. 7 The increased viscosity was due partly to a higher packed cell volume and partly to a higher fibrinogen concentration; plasma viscosity was not significantly increased. These differences could not be explained by smoking history. These results suggest an association between increased blood viscosity and extensive coronary artery disease in men, which merits further investigation.
Introduction
Increased blood viscosity has been described in patients with clinical manifestations of occlusive arterial disease (previous myocardial infarction, angina, claudication) compared with control subjects.'-3 The relation of viscosity to the extent of coronary artery occlusion-the most important determinant of mortality in ischaemic heart disease 4-is, however, not known. We therefore studied blood viscosity and its major determinants (packed cell volume, plasma fibrinogen concentration, and plasma viscosity) in relation to the extent of coronary occlusion in men undergoing coronary arteriography.
